ArriVent BioPharma, Inc. Common Stock (AVBP) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Newtown Square, アメリカ. 現CEOは Zhengbin Yao.
AVBP を有する IPO日 2024-01-26, 52 名の正社員, に上場 NASDAQ Global Market, 時価総額 $1.22B.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
